Dan Pollyea, MD, Discusses Venetoclax For Patients With AML Harboring IDH Mutations

News
Video

Pollyea discussed the rationale behind a study of venetoclax and azacitidine for patients with acute myeloid leukemia with IDH mutations

In an interview with CancerNetwork®, Daniel A. Pollyea, MD of the University of Colorado Cancer Center, discussed the rationale behind a study of venetoclax (Venclexta) and azacitidine (Vidaza) for patients with acute myeloid leukemia with IDH mutations.

Transcription:

What this study explores is the particular subset of patients who have IDH mutation[s]. We’ve known from the very beginning of the clinical experience with venetoclax that IDH patients respond even better than the patients who don’t have an IDH mutation. So this study really is the largest look at that, with an opportunity to look at several 100 patients with IDH mutations and what their outcomes were with venetoclax-based regimens, and then look at the placebo group, as well, that didn’t receive venetoclax. So, I think this helps answer a lot of questions that folks have had regarding to what degree this impacts outcomes, and it’s a pretty large degree of response.

Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
Related Content